Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $119.96. Gilead Sciences ( NASDAQ:GILD – Get Free Report ) last released its earnings results on Tuesday, February 11th.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Now lessons learned from the ... FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal. MiroBio was formed in 2019 to ...

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

One such character is Robin, who after training with the Revolutionary Army for two years during One Piece's time skip, didn’t seem to pick up what could be her most powerful upgrade ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.